Anti-hepatitis B virus drugs in clinical and preclinical development
Authors:
- 1 April 2008
- journal article
- Published by Elsevier in Virologica Sinica
- Vol. 23 (2) , 137-145
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogueProceedings of the National Academy of Sciences of the United States of America, 2007
- Chronic hepatitis BHepatology, 2007
- Pradefovir MesilateDrugs of the Future, 2007
- Identification of a structural motif crucial for infectivity of hepatitis B virusesProceedings of the National Academy of Sciences, 2006
- A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis BGastroenterology, 2005
- Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infectionAntiviral Research, 2004
- Pharmacokinetics of PeginterferonsSeminars in Liver Disease, 2003
- Hepatitis B virus: old, new and future approaches to antiviral treatmentJournal of Antimicrobial Chemotherapy, 2003
- Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In VitroAntimicrobial Agents and Chemotherapy, 2002
- Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine–famciclovir or lamivudine–ganciclovirEuropean Journal of Gastroenterology & Hepatology, 2002